Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor

The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug develo...

Full description

Saved in:
Bibliographic Details
Published inVirology (New York, N.Y.) Vol. 556; pp. 73 - 78
Main Authors O'Brien, Amornrat, Chen, Da-Yuan, Hackbart, Matthew, Close, Brianna J., O'Brien, Timothy E., Saeed, Mohsan, Baker, Susan C.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors. •Coronavirus 3CLpro activity is efficiently measured using a luciferase-based biosensor.•Small molecule inhibitors of 3CLpro block activation of the biosensor.•Polyclonal antiserum raised against SARS-CoV 3CLpro recognizes SARS-CoV-2 3CLpro in WB and IF assays.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0042-6822
1096-0341
1096-0341
DOI:10.1016/j.virol.2021.01.010